The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)
Abstract
PURPOSE: Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC). METHODS: In this open-label, phase III trial, patients with advanced HCC, previously untreated with systemic therapy, were randomly assigned in a 1:1 ratio to receive HAIC-FO or sorafenib. The primary end point was overall survival (OS) in the intention-to-treat population. An exploratory model for predicting the efficacy of HAIC-FO on the basis of genomic sequencing was developed. RESULTS: Between May 2017 and May 2020, 262 patients were randomly assigned. The median tumor size was 11.2 cm (interquartile range, 8.5-13.7 cm). Macrovascular invasion was present in 65.6%, and the percentage of patients with > 50% tumor volume involvement of the liver and/or Vp-4 portal vein tumor thrombosis was 49.2%. At data cutoff (October 31, 2020), median OS was 13.9 months for HAIC-FO and 8.2 for sorafenib (hazard ratio [HR] 0.408; 95% CI, 0.301 to 0.552; P < .001). Tumor downstaging occurred in 16 (12.3% of 130) patients receiving HAIC-FO, including 15 receiving curative surgery or ablation, and finally achieving a median OS of 20.8 months, with a 1-year OS rate of 93.8%. In high-risk subpopulations, OS was significantly longer with HAIC-FO than with sorafenib (10.8 months v 5.7 months; HR 0.343; 95% CI, 0.219 to 0.538; P < .001). A newly developed 15-mutant-gene prediction model identified 83% of patients with response to HAIC-FO. HAIC-FO responders had longer OS than HAIC-FO nonresponders (19.3 months v 10.6 months; HR 0.323; 95% CI, 0.186 to 0.560; P = .002). CONCLUSION: HAIC-FO achieved better survival outcomes than sorafenib in advanced HCC, even in association with a high intrahepatic disease burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Chow, P. K. H., Gandhi, M., Tan, S.-B., Khin, M. W., Khasbazar, A., Ong, J., Choo, S. P., Cheow, P. C., Chotipanich, C., Lim, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0892 · Cited by 658
Randomization and allocation concealment: a practical guide for researchers
Doig, G. S., & Simpson, F. (2005) · Journal of Critical Care · doi:10.1016/j.jcrc.2005.04.005 · Cited by 656
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., Zhou, Y., Wu, X., Xu, L., Wei, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0250 · Cited by 548
Self-citationSystemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
Tandon, P., & Garcia‐Tsao, G. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01957.x · Cited by 354
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., Zhang, Z., Zheng, L., Deng, H., Li, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.008 · Cited by 281
Self-citationChan, S. L., Mo, F. K. F., Johnson, P. J., Hui, E. P., Ma, B. B. Y., Ho, W. M., Lam, K. C., Chan, A. T. C., Mok, T. S. K., & Yeo, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8151 · Cited by 252
Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G. S., Ikeda, M., Lim, H.-Y., Ho, G. F., Choo, S. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.001 · Cited by 234
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
Nault, J., Martin, Y., Caruso, S., Hirsch, T. Z., Bayard, Q., Calderaro, J., Charpy, C., Copie‐Bergman, C., Ziol, M., Bioulac‐Sage, P., et al. (2020) · Hepatology · doi:10.1002/hep.30811 · Cited by 207
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Teufel, M., Seidel, H., Köchert, K., Meinhardt, G., Finn, R. S., Llovet, J. M., & Bruix, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.261 · Cited by 202
Jackson, R., Psarelli, E., Berhane, S., Khan, H., & Johnson, P. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5197 · Cited by 155
Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-314138 · Cited by 124
Self-citationUeshima, K., Ogasawara, S., Ikeda, M., Yasui, Y., Terashima, T., Yamashita, T., Obi, S., Sato, S., Aikata, H., Ohmura, T., et al. (2020) · Liver Cancer · doi:10.1159/000508724 · Cited by 112
Shao, Y., Liu, T., Hsu, C., Lu, L., Shen, Y., Lin, Z., Cheng, A., & Hsu, C. (2019) · Liver International · doi:10.1111/liv.14210 · Cited by 108
Memon, K., Kulik, L., Lewandowski, R. J., Wang, E., Ryu, R. K., Riaz, A., Nikolaidis, P., Miller, F. H., Yaghmai, V., Baker, T., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.020 · Cited by 95
Kelley, R. K., Meyer, T., Rimassa, L., Merle, P., Park, J., Yau, T. C. C., Chan, S. L., Blanc, J., Tam, V. C., Tran, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3884 · Cited by 86
Finn, R. S., Kudo, M., Cheng, A., Wyrwicz, L. S., Ngan, R. K. C., Blanc, J., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4219 · Cited by 81
Zhu, A. X., Finn, R. S., Kang, Y., Yen, C.-J., Galle, P. R., Llovet, J. M., Assénat, E., Brandi, G., Motomura, K., Ohno, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01260-w · Cited by 70
Assessing the fit of parametric cure models
Wileyto, E. P., Li, Y., Chen, J., & Heitjan, D. F. (2012) · Biostatistics · doi:10.1093/biostatistics/kxs043 · Cited by 56
Berhane, S., Fox, R., García‐Fiñana, M., Cucchetti, A., & Johnson, P. J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0488-4 · Cited by 37
Lyu, N., Kong, Y., Pan, T., Mu, L., Li, S., Liu, Y., Deng, H., Li, J., Shi, M., Xu, L., et al. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.09.004 · Cited by 34
Self-citationMu, L., Sun, L., Pan, T., Lyu, N., Li, S., Li, X., Wang, J., Xie, Q., Deng, H., Zheng, L., et al. (2017) · International Journal of Hyperthermia · doi:10.1080/02656736.2017.1318332 · Cited by 29
Self-citation
Cited by
Management of Hepatocellular Carcinoma: A Review
Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 763
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Xie, D., Shi, J., Zhou, J., Fan, J., & Gao, Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0402 · Cited by 177
Metadata
- Authors
- Lyu, N., Wang, X., Li, J.-B., Lai, J.-F., Chen, Q.-F., Li, S.-L., Deng, H.-J., He, M., Mu, L.-W., & Zhao, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-02-10
- Volume
- 40
- Issue
- 5
- Pages
- 468-480
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4200035583
- Cited by
- 291
- References
- 30
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.